Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2025 06:11 ET | Source: Research and Markets

Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035: Regulatory Challenges and Market Barriers in NASH/MASH Drug Approval

Dublin, April 09, 2025 (GLOBE NEWSWIRE) -- The "Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Liver...
February 28, 2025 06:34 ET | Source: Research and Markets

Hepatitis B Therapeutics Competitive Landscape Report: 184 Molecules in the Pipeline - 1 Asset in Pre-registration Stage, 1 Asset in Phase III Development, and 36 Assets in Phase II Development

Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Hepatitis B Therapeutics: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven...
June 13, 2024 06:59 ET | Source: Research and Markets

Comprehensive Overview of ASC22 (Envafolimab): Mechanism, Dosage, Global R&D, Regulatory Milestones, Patents, Sales Forecast till 2032, and SWOT Analysis in Chronic Hepatitis B

Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "ASC22 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.ASC22, also known as envafolimab,...
May 03, 2024 05:45 ET | Source: Research and Markets

VEMLIDY's Impact on Chronic Hepatitis B Treatment Landscape Through 2032

Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "VEMLIDY Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report addresses crucial...
April 30, 2024 06:53 ET | Source: Research and Markets

Entecavir for Chronic Hepatitis B in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2024-2032

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Entecavir Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.A thorough market analysis on...
April 22, 2024 09:52 ET | Source: Research and Markets

BRII-835 + BRII-179 for Chronic Hepatitis B in 7MM: Market Size, Forecast, and Emerging Insights 2019-2032

Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering."BRII-835 +...
April 18, 2024 09:20 ET | Source: Research and Markets

Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032

Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
September 09, 2014 03:00 ET | Source: OnCore Biopharma, Inc.

OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection

OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...